Indication |
For the management of anxiety disorders or for the short-term
relief of the symptoms of anxiety or anxiety associated with depressive
symptoms. |
Pharmacodynamics |
Cinolazepam is a drug which is a benzodiazepine derivative. It
possesses anxiolytic, anticonvulsant, sedative and skeletal muscle
relaxant properties. Cinolazepam is not approved for sale in the United
States or Canada. |
Mechanism of action |
Cinolazepam binds to central benzodiazepine receptors which
interact allosterically with GABA receptors. This potentiates the
effects of the inhibitory neurotransmitter GABA, increasing the
inhibition of the ascending reticular activating system and blocking the
cortical and limbic arousal that occurs following stimulation of the
reticular pathways. |
Absorption |
Bioavailability following oral administration is 90-100%. |
Volume of distribution |
Not Available |
Protein binding |
Not Available |
Metabolism |
Hepatic. |
Route of elimination |
Not Available |
Half life |
9 hours |
Clearance |
Not Available |
Toxicity |
The onset of impairment of consciousness is relatively rapid in
benzodiazepine poisoning. Onset is more rapid following larger doses and
with agents of shorter duration of action. The most common and initial
symptom is somnolence. This may progress to coma Grade I or Grade II
following very large ingestions. |
Comments
Post a Comment